You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 286 No. 12, September 26, 2001 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communication
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (65)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Prognosis/ Outcomes
 •Cardiac Diagnostic Tests
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Comparison of 2 Methods for Calculating Adjusted Survival Curves From Proportional Hazards Models

William A. Ghali, MD,MPH; Hude Quan, MD,PhD; Rollin Brant, PhD; Guy van Melle, PhD; Colleen M. Norris, MSc; Peter D. Faris, PhD; P. Diane Galbraith, BN; Merril L. Knudtson, MD; for the APPROACH (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease) Investigators

JAMA. 2001;286:1494-1497.

Context  Adjusted survival curves are often presented in medical research articles. The most commonly used method for calculating such curves is the mean of covariates method, in which average values of covariates are entered into a proportional hazards regression equation. Use of this method is widespread despite published concerns regarding the validity of resulting curves.

Objective  To compare the mean of covariates method to the less widely used corrected group prognosis method in an analysis evaluating survival in patients with and without diabetes. In the latter method, a survival curve is calculated for each level of covariates, after which an average survival curve is calculated as a weighted average of the survival curves for each level of covariates.

Design, Setting, and Patients  Analysis of cohort study data from 11 468 Alberta residents undergoing cardiac catheterization between January 1, 1995, and December 31, 1996.

Main Outcome Measures  Crude and risk-adjusted survival for up to 3 years after cardiac catheterization in patients with vs without diabetes, analyzed by the mean of covariates method vs the corrected group prognosis method.

Results  According to the mean of covariates method, adjusted survival at 1044 days was 94.1% and 94.9% for patients with and without diabetes, respectively, with misleading adjusted survival curves that fell above the unadjusted curves. With the corrected group prognosis method, the corresponding survival values were 91.3% and 92.4%, with curves that fell more appropriately between the unadjusted curves.

Conclusions  Misleading adjusted survival curves resulted from using the mean of covariates method of analysis for our data. We recommend using the corrected group prognosis method for calculating risk-adjusted curves.


Author Affiliations: Departments of Medicine (Drs Ghali, Knudtson and Ms Galbraith) and Community Health Sciences (Drs Ghali, Quan, Brant, and Faris), University of Calgary, Calgary, Alberta; Department of Public Health Sciences, University of Alberta, Edmonton, Alberta (Ms Norris); and the Institute for Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland (Dr van Melle).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aortic Valve Replacement for Patients With Severe Aortic Stenosis: Risk Factors and Their Impact on 30-Month Mortality.
Hannan et al.
Ann. Thorac. Surg. 2009;87:1741-1749.
ABSTRACT | FULL TEXT  

Comparison of Drug-Eluting Stents and Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Disease: Three-Year Follow-Up Results From a Single Institution
Li et al.
Circulation 2009;119:2040-2050.
ABSTRACT | FULL TEXT  

Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation
Kimura et al.
Circulation 2009;119:987-995.
ABSTRACT | FULL TEXT  

Prediction of survival after coronary revascularization: modeling short-term, mid-term, and long-term survival.
MacKenzie et al.
Ann. Thorac. Surg. 2009;87:463-472.
ABSTRACT | FULL TEXT  

Incomplete Revascularization in the Era of Drug-Eluting Stents: Impact on Adverse Outcomes
Hannan et al.
J Am Coll Cardiol Intv 2009;2:17-25.
ABSTRACT | FULL TEXT  

Long-Term Results of Heart Operations Performed by Surgeons-in-Training
Stoica et al.
Circulation 2008;118:S1-S6.
ABSTRACT | FULL TEXT  

Betel nut chewing is associated with increased risk of cardiovascular disease and all-cause mortality in Taiwanese men
Lin et al.
Am. J. Clin. Nutr. 2008;87:1204-1211.
ABSTRACT | FULL TEXT  

Comparison of Coronary Artery Stenting Outcomes in the Eras Before and After the Introduction of Drug-Eluting Stents
Hannan et al.
Circulation 2008;117:2071-2078.
ABSTRACT | FULL TEXT  

Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction
Hannan et al.
J Am Coll Cardiol Intv 2008;1:129-135.
ABSTRACT | FULL TEXT  

Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease
Hannan et al.
NEJM 2008;358:331-341.
ABSTRACT | FULL TEXT  

Temporal trends in the frequency and longer-term outcome of heart failure complicating myocardial infarction
Najafi et al.
Eur J Heart Fail 2007;9:879-885.
ABSTRACT | FULL TEXT  

Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure
Keyhan et al.
Eur J Heart Fail 2007;9:594-601.
ABSTRACT | FULL TEXT  

Exploring the Treatment-Risk Paradox in Coronary Disease
McAlister et al.
Arch Intern Med 2007;167:1019-1025.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy
Agus et al.
JCO 2007;25:675-681.
ABSTRACT | FULL TEXT  

Evaluation of Preoperative Therapy for Pancreatic Cancer Using a Prognostic Nomogram
White et al.
Ann. Surg. Oncol. 2006;13:1485-1492.
ABSTRACT | FULL TEXT  

Revascularization in patients with heart failure.
Tsuyuki et al.
CMAJ 2006;175:361-365.
ABSTRACT | FULL TEXT  

The Prognostic Importance of Nonsignificant Left Main Coronary Artery Disease in Patients Undergoing Percutaneous Coronary Intervention
Gyenes et al.
J Am Coll Cardiol 2006;48:276-280.
ABSTRACT | FULL TEXT  

Impact of Completeness of Percutaneous Coronary Intervention Revascularization on Long-Term Outcomes in the Stent Era
Hannan et al.
Circulation 2006;113:2406-2412.
ABSTRACT | FULL TEXT  

Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: An analysis of 5018 hospital- and 712 population-based cases
Sun et al.
J. Thorac. Cardiovasc. Surg. 2006;131:1014-1020.
ABSTRACT | FULL TEXT  

Smoking and deaths between 40 and 70 years of age in women and men.
Vollset et al.
ANN INTERN MED 2006;144:381-389.
ABSTRACT | FULL TEXT  

Gender Differences in Outcomes After Hospital Discharge From Coronary Artery Bypass Grafting
Guru et al.
Circulation 2006;113:507-516.
ABSTRACT | FULL TEXT  

Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial
Beinart et al.
J Am Coll Cardiol 2005;46:761-769.
ABSTRACT | FULL TEXT  

Long-Term Outcomes of Coronary-Artery Bypass Grafting versus Stent Implantation
Hannan et al.
NEJM 2005;352:2174-2183.
ABSTRACT | FULL TEXT  

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
Finazzi et al.
Blood 2005;105:2664-2670.
ABSTRACT | FULL TEXT  

Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation
Weintraub et al.
J Am Coll Cardiol 2005;45:838-845.
ABSTRACT | FULL TEXT  

Perioperative Stroke and Long-Term Survival After Coronary Bypass Graft Surgery
Dacey et al.
Ann. Thorac. Surg. 2005;79:532-536.
ABSTRACT | FULL TEXT  

The high risk of stroke immediately after transient ischemic attack: A population-based study
Hill et al.
Neurology 2004;62:2015-2020.
ABSTRACT | FULL TEXT  

Therapy Switching in Patients Receiving Long-Acting Opioids
Berger et al.
The Annals of Pharmacotherapy 2004;38:389-395.
ABSTRACT | FULL TEXT  

Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A retrospective cohort study
Delea et al.
Diabetes Care 2003;26:2983-2989.
ABSTRACT | FULL TEXT  

Care and Outcomes of Patients Newly Hospitalized for Heart Failure in the Community Treated by Cardiologists Compared With Other Specialists
Jong et al.
Circulation 2003;108:184-191.
ABSTRACT | FULL TEXT  

Can Universal Access to Health Care Eliminate Health Inequities Between Children of Poor and Nonpoor Families?: A Case Study of Childhood Asthma in Alberta
Sin et al.
Chest 2003;124:51-56.
ABSTRACT | FULL TEXT  

Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?
Sin and Man
Eur Respir J 2003;21:260-266.
ABSTRACT | FULL TEXT  

Analysis of Clinical Stage T2 Prostate Cancer: Do Current Subclassifications Represent an Improvement?
Cagiannos et al.
JCO 2002;20:2025-2030.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.